<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="ACE inhibitor,ACE inhibitors,Major Drug Groups,ACE inhibitors,Major Drug Groups,1956,ATC code C09,Adverse drug reaction,Aldosterone,Allergy,Analgesic" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>ACE inhibitor - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">ACE inhibitor</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <div class="thumb tright">
<div class="thumbinner" style="width:202px;"><a href="../../../c/a/p/Image%7ECaptopril.png_97c7.html" class="internal" title="Captopril, the first ACE inhibitor"><img src="../../../upload/thumb/c/c8/Captopril.png/200px-Captopril.png" alt="Captopril, the first ACE inhibitor" width="200" height="127" longdesc="../../../c/a/p/Image%7ECaptopril.png_97c7.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../c/a/p/Image%7ECaptopril.png_97c7.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Captopril, the first ACE inhibitor</div>
</div>
</div>
<p><b>ACE inhibitors</b>, or inhibitors of <a href="../../../a/n/g/Angiotensin-converting_enzyme.html" title="Angiotensin-converting enzyme"><b>A</b>ngiotensin-<b>C</b>onverting <b>E</b>nzyme</a>, are a group of <a href="../../../p/h/a/Pharmaceutical.html" title="Pharmaceutical">pharmaceuticals</a> that are used primarily in treatment of <a href="../../../h/y/p/Hypertension.html" title="Hypertension">hypertension</a> and <a href="../../../c/o/n/Congestive_heart_failure.html" title="Congestive heart failure">congestive heart failure</a>, in most cases as the drugs of first choice.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Clinical_use"><span class="tocnumber">1</span> <span class="toctext">Clinical use</span></a></li>
<li class="toclevel-1"><a href="#The_Renin-Angiotensin-Aldosterone_System_.28RAAS.29"><span class="tocnumber">2</span> <span class="toctext">The Renin-Angiotensin-Aldosterone System (RAAS)</span></a></li>
<li class="toclevel-1"><a href="#Effects_of_ACE_inhibitors"><span class="tocnumber">3</span> <span class="toctext">Effects of ACE inhibitors</span></a></li>
<li class="toclevel-1"><a href="#Adverse_effects"><span class="tocnumber">4</span> <span class="toctext">Adverse effects</span></a></li>
<li class="toclevel-1"><a href="#Examples_of_ACE_inhibitors"><span class="tocnumber">5</span> <span class="toctext">Examples of ACE inhibitors</span></a>
<ul>
<li class="toclevel-2"><a href="#Sulfhydryl-containing_ACE_inhibitors"><span class="tocnumber">5.1</span> <span class="toctext">Sulfhydryl-containing ACE inhibitors</span></a></li>
<li class="toclevel-2"><a href="#Dicarboxylate-containing_ACE_inhibitors"><span class="tocnumber">5.2</span> <span class="toctext">Dicarboxylate-containing ACE inhibitors</span></a></li>
<li class="toclevel-2"><a href="#Phosphonate-containing_ACE_inhibitors"><span class="tocnumber">5.3</span> <span class="toctext">Phosphonate-containing ACE inhibitors</span></a></li>
<li class="toclevel-2"><a href="#Naturally_occurring"><span class="tocnumber">5.4</span> <span class="toctext">Naturally occurring</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Comparative_information"><span class="tocnumber">6</span> <span class="toctext">Comparative information</span></a></li>
<li class="toclevel-1"><a href="#Contraindications_and_precautions"><span class="tocnumber">7</span> <span class="toctext">Contraindications and precautions</span></a></li>
<li class="toclevel-1"><a href="#Angiotensin_II_receptor_antagonists"><span class="tocnumber">8</span> <span class="toctext">Angiotensin II receptor antagonists</span></a>
<ul>
<li class="toclevel-2"><a href="#Use_in_combination_with_ACE_inhibitors"><span class="tocnumber">8.1</span> <span class="toctext">Use in combination with ACE inhibitors</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">9</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Clinical_use" id="Clinical_use"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Clinical use">edit</a>]</span> <span class="mw-headline">Clinical use</span></h2>
<p>Indications for ACE inhibitors include:</p>
<ul>
<li>Prevention of <a href="../../../c/a/r/Cardiovascular.html" title="Cardiovascular">cardiovascular</a> disorders</li>
<li><a href="../../../c/o/n/Congestive_heart_failure.html" title="Congestive heart failure">Congestive heart failure</a></li>
<li><a href="../../../h/y/p/Hypertension.html" title="Hypertension">Hypertension</a></li>
<li>Left <a href="../../../v/e/n/Ventricle_%28heart%29.html" title="Ventricle (heart)">ventricular</a> dysfunction</li>
<li>Prevention of <a href="../../../n/e/p/Nephropathy.html" title="Nephropathy">nephropathy</a> in <a href="../../../d/i/a/Diabetes_mellitus.html" title="Diabetes mellitus">diabetes mellitus</a></li>
</ul>
<p>In several of these indications, ACE inhibitors are used first-line as several agents in the class have been clinically shown to be superior to other classes of drugs in the reduction of <a href="../../../m/o/r/Morbidity.html" title="Morbidity">morbidity</a> and <a href="../../../m/o/r/Mortality.html" title="Mortality">mortality</a>.</p>
<p>ACE inhibitors are often combined with <a href="../../../d/i/u/Diuretic.html" title="Diuretic">diuretics</a> in the control of hypertension (usually a <a href="../../../t/h/i/Thiazide.html" title="Thiazide">thiazide</a>), when an ACE inhibitor alone proves insufficient; and in chronic heart failure (usually <a href="../../../f/u/r/Furosemide.html" title="Furosemide">furosemide</a>) for improved symptomatic control. Thus there exists, on the market, combination products combining an ACE inhibitor with a thiazide (usually <a href="../../../h/y/d/Hydrochlorothiazide.html" title="Hydrochlorothiazide">hydrochlorothiazide</a>) in a single tablet to allow easy administration by patients.</p>
<p><a name="The_Renin-Angiotensin-Aldosterone_System_.28RAAS.29" id="The_Renin-Angiotensin-Aldosterone_System_.28RAAS.29"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: The Renin-Angiotensin-Aldosterone System (RAAS)">edit</a>]</span> <span class="mw-headline">The Renin-Angiotensin-Aldosterone System (RAAS)</span></h2>
<p>This system is activated in response to hypotension, decreased sodium delivery, decreased blood volume and sympathetic stimulation. In such a situation, the kidneys release renin which cleaves the liver derived angiotensinogen into Angiotensin I. Angiotensin I is then converted to angiotensin II via the angiotensin-converting-enzyme (ACE) in the pulmonary circulation. The system in general aims to increase blood pressure.</p>
<p><a name="Effects_of_ACE_inhibitors" id="Effects_of_ACE_inhibitors"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Effects of ACE inhibitors">edit</a>]</span> <span class="mw-headline">Effects of ACE inhibitors</span></h2>
<p>ACE inhibitors lower <a href="../../../a/r/t/Arteriole.html" title="Arteriole">arteriolar</a> resistance and increase venous capacitance; increase <a href="../../../c/a/r/Cardiac_output.html" title="Cardiac output">cardiac output</a> and <a href="../../../c/a/r/Cardiac_index.html" title="Cardiac index">cardiac index</a>, stroke work and <a href="../../../s/t/r/Stroke_volume.html" title="Stroke volume">volume</a>, lower renovascular resistance, and lead to increased <a href="../../../n/a/t/Natriuresis.html" title="Natriuresis">natriuresis</a> (excretion of <a href="../../../s/o/d/Sodium.html" title="Sodium">sodium</a> in the <a href="../../../u/r/i/Urine.html" title="Urine">urine</a>).</p>
<p>Normally, angiotensin II will have the following effects:<br />
- vasoconstriction (narrowing of blood vessels)<br />
- cardiac hypertrophy<br />
- stimulate the adrenal cortex to release <a href="../../../a/l/d/Aldosterone.html" title="Aldosterone">aldosterone</a>, a hormone which acts on kidney tubules to retain sodium and chloride ions and excrete potassium. Sodium is a "water-holding" molecule, so water is also retained. This leads to increased blood volume, hence an increase in blood pressure.<br />
- stimulate the posterior pituitary into releasing vasopressin (also known as anti-diuretic hormone (ADH)) which also acts on the kidneys to increase water retention.</p>
<p>With ACE inhibitor use, the effects of angiotensin II are prevented, leading to decreased blood pressure.</p>
<p><a href="../../../e/p/i/Epidemiology.html" title="Epidemiology">Epidemiological</a> and clinical studies have shown that ACE inhibitors reduce the progress of <a href="../../../d/i/a/Diabetic_nephropathy.html" title="Diabetic nephropathy">diabetic nephropathy</a> independently from their blood pressure-lowering effect. This action of ACE inhibitors is utilised in the prevention of diabetic <a href="../../../r/e/n/Renal_failure.html" title="Renal failure">renal failure</a>.</p>
<p>ACE inhibitors have been shown to be effective for indications other than hypertension even in patients with normal blood pressure. The use of a maximum dose of ACE inhibitors in such patients (including for prevention of diabetic nephropathy, congestive heart failure, prophylaxis of cardiovascular events) is justified because it improves clinical outcomes, independent of the blood pressure lowering effect of ACE inhibitors. Such therapy, of course, requires careful and gradual titration of the dose to prevent the patient suffering from the effects of rapidly decreasing their blood pressure (dizziness, fainting, <i>etc</i>).</p>
<p><a name="Adverse_effects" id="Adverse_effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Adverse effects">edit</a>]</span> <span class="mw-headline">Adverse effects</span></h2>
<p>Common <a href="../../../a/d/v/Adverse_drug_reaction.html" title="Adverse drug reaction">adverse drug reactions</a> (≥1% of patients) include: <a href="../../../h/y/p/Hypotension.html" title="Hypotension">hypotension</a>, <a href="../../../c/o/u/Cough.html" title="Cough">cough</a>, <a href="../../../h/y/p/Hyperkalemia.html" title="Hyperkalemia">hyperkalemia</a>, <a href="../../../h/e/a/Headache.html" title="Headache">headache</a>, <a href="../../../v/e/r/Vertigo_%28medical%29.html" title="Vertigo (medical)">dizziness</a>, <a href="../../../f/a/t/Fatigue_%28physical%29.html" title="Fatigue (physical)">fatigue</a>, <a href="../../../n/a/u/Nausea.html" title="Nausea">nausea</a>, renal impairment.<sup id="_ref-AMH2006_0" class="reference"><a href="#_note-AMH2006" title="">[1]</a></sup></p>
<p>A persistent dry cough is a relatively common adverse effect believed to be associated with the increases in <a href="../../../b/r/a/Bradykinin.html" title="Bradykinin">bradykinin</a> levels produced by ACE inhibitors, although the role of bradykinin in producing these symptoms remains disputed by some authors.<sup id="_ref-Okumura2001_0" class="reference"><a href="#_note-Okumura2001" title="">[2]</a></sup> Patients who experience this cough are often switched to <a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Angiotensin II receptor antagonist">angiotensin II receptor antagonists</a>.</p>
<p>Rash and taste disturbances, infrequent with most ACE inhibitors, are more prevalent in <a href="../../../c/a/p/Captopril.html" title="Captopril">captopril</a> and is attributed to its sulfhydryl moiety. This has led to decreased use of captopril in clinical setting, although it is still used in <a href="../../../s/c/i/Scintigraphy.html" title="Scintigraphy">scintigraphy</a> of the kidney.</p>
<p>Renal impairment is a significant adverse effect of all ACE inhibitors, and is associated with their effect on angiotensin II-mediated <a href="../../../h/o/m/Homeostasis.html" title="Homeostasis">homeostatic</a> functions such as renal bloodflow. ACE inhibitors can induce or exacerbate renal impairment in patients with <a href="../../../r/e/n/Renal_artery_stenosis.html" title="Renal artery stenosis">renal artery stenosis</a>. This is especially a problem if the patient is also concomitantly taking an <a href="../../../n/o/n/Non-steroidal_anti-inflammatory_drug.html" title="Non-steroidal anti-inflammatory drug">NSAID</a> and a <a href="../../../d/i/u/Diuretic.html" title="Diuretic">diuretic</a> - the so-called "triple whammy" effect - such patients are at very high risk of developing renal failure.<sup id="_ref-Thomas2000_0" class="reference"><a href="#_note-Thomas2000" title="">[3]</a></sup></p>
<p>Some patients develop <a href="../../../a/n/g/Angioedema.html" title="Angioedema">angioedema</a> due to increased bradykinin levels. There appears to be a genetic predisposition towards this adverse effect in patients who degrade bradykinin slower than average.<sup id="_ref-Molinaro2002_0" class="reference"><a href="#_note-Molinaro2002" title="">[4]</a></sup></p>
<p><a name="Examples_of_ACE_inhibitors" id="Examples_of_ACE_inhibitors"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Examples of ACE inhibitors">edit</a>]</span> <span class="mw-headline">Examples of ACE inhibitors</span></h2>
<p>ACE inhibitors can be divided into three groups based on their molecular structure:</p>
<p><a name="Sulfhydryl-containing_ACE_inhibitors" id="Sulfhydryl-containing_ACE_inhibitors"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Sulfhydryl-containing ACE inhibitors">edit</a>]</span> <span class="mw-headline">Sulfhydryl-containing ACE inhibitors</span></h3>
<ul>
<li><a href="../../../c/a/p/Captopril.html" title="Captopril">Captopril</a> (Capoten®), the first ACE inhibitor</li>
</ul>
<p><a name="Dicarboxylate-containing_ACE_inhibitors" id="Dicarboxylate-containing_ACE_inhibitors"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Dicarboxylate-containing ACE inhibitors">edit</a>]</span> <span class="mw-headline">Dicarboxylate-containing ACE inhibitors</span></h3>
<p>This is the largest group, including:</p>
<ul>
<li><a href="../../../e/n/a/Enalapril.html" title="Enalapril">Enalapril</a> (Vasotec®/Renitec®)</li>
<li><a href="../../../r/a/m/Ramipril.html" title="Ramipril">Ramipril</a> (Altace®/Tritace®/Ramace®/Ramiwin®)</li>
<li><a href="../../../q/u/i/Quinapril.html" title="Quinapril">Quinapril</a> (Accupril®)</li>
<li><a href="../../../p/e/r/Perindopril.html" title="Perindopril">Perindopril</a> (Coversyl®)</li>
<li><a href="../../../l/i/s/Lisinopril.html" title="Lisinopril">Lisinopril</a> (Lisodur®/Lopril®/Prinivil®/Zestril®)</li>
<li><a href="../../../b/e/n/Benazepril.html" title="Benazepril">Benazepril</a> (Lotensin®)</li>
</ul>
<p><a name="Phosphonate-containing_ACE_inhibitors" id="Phosphonate-containing_ACE_inhibitors"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Phosphonate-containing ACE inhibitors">edit</a>]</span> <span class="mw-headline">Phosphonate-containing ACE inhibitors</span></h3>
<ul>
<li><a href="../../../f/o/s/Fosinopril.html" title="Fosinopril">Fosinopril</a> (Monopril®), the only member</li>
</ul>
<p><a name="Naturally_occurring" id="Naturally_occurring"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Naturally occurring">edit</a>]</span> <span class="mw-headline">Naturally occurring</span></h3>
<p>Casokinins and lactokinins are breakdown products of <a href="../../../c/a/s/Casein.html" title="Casein">casein</a> and <a href="../../../w/h/e/Whey.html" title="Whey">whey</a> that occur naturally after ingestion of <a href="../../../m/i/l/Milk.html" title="Milk">milk</a> products, especially <a href="../../../s/o/u/Soured_milk.html" title="Soured milk">sour milk</a>. Their role in blood pressure control is uncertain.<sup id="_ref-FitzGerald2004_0" class="reference"><a href="#_note-FitzGerald2004" title="">[5]</a></sup></p>
<p><a name="Comparative_information" id="Comparative_information"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Comparative information">edit</a>]</span> <span class="mw-headline">Comparative information</span></h2>
<p>Comparatively, all ACE inhibitors have similar antihypertensive efficacy when equivalent doses are administered. The main point-of-difference lies with captopril, the first ACE inhibitor, which has a shorter duration of action and increased incidence of certain adverse effects (cf. <a href="../../../c/a/p/Captopril.html" title="Captopril">captopril</a>).</p>
<p>Certain agents in the ACE inhibitor class have been proven, in large clinical studies, to reduce mortality post-<a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">myocardial infarction</a>, prevent development of heart failure, <i>etc</i>. While these effects are likely to be class-effects, good <a href="../../../e/v/i/Evidence-based_medicine.html" title="Evidence-based medicine">evidence-based medicine</a> practice would direct the use of those agents with established clinical efficacy.</p>
<p><a name="Contraindications_and_precautions" id="Contraindications_and_precautions"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Contraindications and precautions">edit</a>]</span> <span class="mw-headline">Contraindications and precautions</span></h2>
<p>The ACE inhibitors are contraindicated in patients with:</p>
<ul>
<li>Previous <a href="../../../a/n/g/Angioedema.html" title="Angioedema">angioedema</a> associated with ACE inhibitor therapy</li>
<li><a href="../../../r/e/n/Renal_artery_stenosis.html" title="Renal artery stenosis">Renal artery stenosis</a> (bilateral, or unilateral with a solitary functioning kidney)</li>
</ul>
<p>ACE inhibitors should be used with caution in patients with:</p>
<ul>
<li>Impaired renal function</li>
<li><a href="../../../a/o/r/Aortic_valve_stenosis.html" title="Aortic valve stenosis">Aortic valve stenosis</a> or cardiac outflow obstruction</li>
<li><a href="../../../h/y/p/Hypovolaemia.html" title="Hypovolaemia">Hypovolaemia</a> or <a href="../../../d/e/h/Dehydration.html" title="Dehydration">dehydration</a></li>
<li><a href="../../../h/a/e/Haemodialysis.html" title="Haemodialysis">Haemodialysis</a> with high flux polyacrylonitrile membranes</li>
</ul>
<p>ACE inhibitors are <a href="../../../a/u/s/Australian_Drug_Evaluation_Committee_3edb.html" title="Australian Drug Evaluation Committee">ADEC</a> <a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy category</a> D, and should be avoided in women who are likely to become pregnant.<sup id="_ref-AMH2006_1" class="reference"><a href="#_note-AMH2006" title="">[1]</a></sup> In the U.S., ACE inhibitors are required to be labelled with a "<a href="../../../b/l/a/Black_box_warning.html" title="Black box warning">black box</a>" warning concerning the risk of birth defects when taking during the second and third <a href="../../../t/r/i/Trimester.html" title="Trimester">trimester</a>. It has also been found that use of ACE inhibitors in the first trimester is also associated with a risk of major <a href="../../../c/o/n/Congenital_malformation.html" title="Congenital malformation">congenital malformations</a>, particularly affecting the <a href="../../../c/i/r/Circulatory_system.html" title="Circulatory system">cardiovascular</a> and <a href="../../../c/e/n/Central_nervous_system.html" title="Central nervous system">central nervous systems</a>.<sup id="_ref-Cooper2006_0" class="reference"><a href="#_note-Cooper2006" title="">[6]</a></sup></p>
<p>Potassium supplementation should be used with caution and under medical supervision owing to the <a href="../../../h/y/p/Hyperkalemia.html" title="Hyperkalemia">hyperkalaemic</a> effect of ACE inhibitors.</p>
<p><a name="Angiotensin_II_receptor_antagonists" id="Angiotensin_II_receptor_antagonists"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Angiotensin II receptor antagonists">edit</a>]</span> <span class="mw-headline">Angiotensin II receptor antagonists</span></h2>
<p>ACE inhibitors share many common characteristics with another class of cardiovascular drugs called <a href="../../../a/n/g/Angiotensin_II_receptor_antagonist_7881.html" title="Angiotensin II receptor antagonist">angiotensin II receptor antagonists</a>, which are often used when patients are intolerant of the adverse effects produced by ACE inhibitors. ACE inhibitors do not completely prevent the formation of angiotensin II, as there are other conversion pathways, and so angiotensin II receptor antagonists may be useful because they act to prevent the action of angiotensin II at the AT<sub>1</sub> receptor.</p>
<p><a name="Use_in_combination_with_ACE_inhibitors" id="Use_in_combination_with_ACE_inhibitors"></a></p>
<h3><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: Use in combination with ACE inhibitors">edit</a>]</span> <span class="mw-headline">Use in combination with ACE inhibitors</span></h3>
<p>While counterintuitive at first glance, the combination therapy of angiotensin II receptor antagonists with ACE inhibitors may be superior to either agent alone. This combination may increase levels of bradykinin while blocking the generation of angiotensin II and its activity at the AT<sub>1</sub> receptor. This 'dual blockade' may be more effective than using an ACE inhibitor alone, because angiotensin II can be generated via non-ACE-dependent pathways. Preliminary studies suggest that this combination of pharmacologic agents may be advantageous in the treatment of <a href="../../../e/s/s/Essential_hypertension.html" title="Essential hypertension">essential hypertension</a>, chronic <a href="../../../h/e/a/Heart_failure.html" title="Heart failure">heart failure</a>, and <a href="../../../n/e/p/Nephropathy.html" title="Nephropathy">nephropathy</a>.<sup id="_ref-Luno2005_0" class="reference"><a href="#_note-Luno2005" title="">[7]</a></sup><sup id="_ref-vandeWal2005_0" class="reference"><a href="#_note-vandeWal2005" title="">[8]</a></sup> However, more studies are needed to confirm these highly preliminary results. While statistically significant results have been obtained for its role in treating hypertension, clinical significance may be lacking.<sup id="_ref-Finnegan2003_0" class="reference"><a href="#_note-Finnegan2003" title="">[9]</a></sup></p>
<p>Patients with heart failure may benefit from the combination in terms of reducing <a href="../../../m/o/r/Morbidity.html" title="Morbidity">morbidity</a> and <a href="../../../v/e/n/Ventricular_remodeling.html" title="Ventricular remodeling">ventricular remodeling</a>.<sup id="_ref-Krum2004_0" class="reference"><a href="#_note-Krum2004" title="">[10]</a></sup><sup id="_ref-Solomon2005_0" class="reference"><a href="#_note-Solomon2005" title="">[11]</a></sup></p>
<p>The most compelling evidence has been found for the treatment of nephropathy: this combination therapy partially reversed the <a href="../../../p/r/o/Proteinuria.html" title="Proteinuria">proteinuria</a> and also exhibited a renoprotective effect in patients afflicted with <a href="../../../d/i/a/Diabetic_nephropathy.html" title="Diabetic nephropathy">diabetic nephropathy</a>, (Luno et al., 2005) and pediatric <a href="../../../i/g/a/IgA_nephropathy_62a2.html" title="IgA nephropathy">IgA nephropathy</a>.<sup id="_ref-Yang2005_0" class="reference"><a href="#_note-Yang2005" title="">[12]</a></sup></p>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>The first step in the development of (ACE) inhibitors was the discovery of angiotensin converting enzyme (ACE) in the Plasma by Leonard T. Skeggs and his colleagues in <a href="../../../1/9/5/1956.html" title="1956">1956</a>. The conversion of the inactive angiotensin I to the potent angiotensin II was thought to take place in the plasma. However, in 1967, Kevin K. F. Ng and <a href="../../../j/o/h/John_R._Vane_c3bd.html" title="John R. Vane">John R. Vane</a> showed that the plasma (ACE) was too slow to account for the conversion of angiotensin I to angiotensin II in vivo. Subsequent investigation showed that rapid conversion occur during its passage through the pulmonary circulation.<sup id="_ref-Kevin_0" class="reference"><a href="#_note-Kevin" title="">[13]</a></sup></p>
<p><a href="../../../b/r/a/Bradykinin.html" title="Bradykinin">Bradykinin</a> is rapidly inactivated in the circulating blood and it disappears completely in a single passage through the pulmonary circulation. Angiotensin I also disappears in the pulmnonary circulation due to its conversion to angiotensin II. Furthermore, angiotensin II passes through the lungs without any loss. The inactivation of bradykinin and the conversion of angiotensin I to angiotensin II in the lungs was thought to be caused by the same enzyme.<sup id="_ref-Kevin2_0" class="reference"><a href="#_note-Kevin2" title="">[14]</a></sup> In 1970, Ng and Vane using bradykinin potentiating factor (BPF) provided by <a href="../../../s/%C3%A9/r/S%C3%A9rgio_Henrique_Ferreira_6235.html" title="Sérgio Henrique Ferreira">Sérgio Henrique Ferreira</a> showed that the conversion of angiotensin I to angiotensin II was inhibited during its passage through the pulmonary circulation.<sup id="_ref-Kevin3_0" class="reference"><a href="#_note-Kevin3" title="">[15]</a></sup></p>
<p>Bradykinin potentiating factor (BPF) is derived from the venom of the pit viper (<i><a href="../../../b/o/t/Bothrops_jararaca.html" title="Bothrops jararaca">Bothrops jararaca</a></i>). It is a family of peptides and its potentiating action is linked to inhibition of bradykinin by ACE. Molecular analysis of BPF yielded a nonapeptide BPF teprotide (SQ 20,881) which showed the greatest (ACE) inhibition potency and hypotensinve effect in vivo. Teprotide had limited clinical value, due to its peptide nature and lack of activity when given orally. In the early 1970s, knowledge of the structure-activity relationship required for inhibition of ACE was growing. David Cushman, <a href="../../../m/i/g/Miguel_Ondetti_a727.html" title="Miguel Ondetti">Miguel Ondetti</a> and colleagues used peptide analogues to study the structure of ACE, using carboxypeptidase A as a model. Their discoveries led to the development of <a href="../../../c/a/p/Captopril.html" title="Captopril">captopril</a>, the first orally-active ACE inhibitor in 1975.</p>
<p>Captopril was approved by the United States <a href="../../../f/o/o/Food_and_Drug_Administration_b75c.html" title="Food and Drug Administration">Food and Drug Administration</a> in 1981. The first non-sulfhydryl-containing (ACE) inhibitor enalapril was marketed two years later. Since then, at least twelve other ACE inhibitors have been marketed.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/c/e/ACE_inhibitor_fd43.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<div class="references-small">
<ol class="references">
<li id="_note-AMH2006">^ <a href="#_ref-AMH2006_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-AMH2006_1" title=""><sup><i><b>b</b></i></sup></a> Rossi S, editor. <a href="../../../a/u/s/Australian_Medicines_Handbook_0c4c.html" title="Australian Medicines Handbook">Australian Medicines Handbook</a> 2006. Adelaide: Australian Medicines Handbook; 2006. <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 0-9757919-2-3</a>.</li>
<li id="_note-Okumura2001"><b><a href="#_ref-Okumura2001_0" title="">^</a></b> Okumura H, Nishimura E, Kariya S, et al. Angiotensin-converting enzyme (ACE) <a href="http://www.jstage.jst.go.jp/article/yakushi/121/3/253/_pdf" class="external text" title="http://www.jstage.jst.go.jp/article/yakushi/121/3/253/_pdf" rel="nofollow">阻害薬誘発性の咳嗽発現とACE遺伝子型,血漿中ブラジキニン,サブスタンスP及びACE阻害薬濃度との関連性</a> [No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients]. Yakugaku Zasshi 2001;121(3):253-7. Japanese. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11265121" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11265121">PMID 11265121</a></li>
<li id="_note-Thomas2000"><b><a href="#_ref-Thomas2000_0" title="">^</a></b> Thomas MC. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. Med J Aust 2000;172(4):184–185. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10772593" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10772593">PMID 10772593</a></li>
<li id="_note-Molinaro2002"><b><a href="#_ref-Molinaro2002_0" title="">^</a></b> Molinaro G, Cugno M, Perez M, et al. <a href="http://jpet.aspetjournals.org/cgi/content/full/303/1/232" class="external text" title="http://jpet.aspetjournals.org/cgi/content/full/303/1/232" rel="nofollow">Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin.</a> J Pharmacol Exp Ther 2002;303:232-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12235256" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12235256">PMID 12235256</a>.</li>
<li id="_note-FitzGerald2004"><b><a href="#_ref-FitzGerald2004_0" title="">^</a></b> FitzGerald RJ, Murray BA, Walsh DJ. <a href="http://jn.nutrition.org/cgi/content/full/134/4/980S" class="external text" title="http://jn.nutrition.org/cgi/content/full/134/4/980S" rel="nofollow">Hypotensive peptides from milk proteins.</a> J Nutr 2004;134:980S-8S. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15051858" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15051858">PMID 15051858</a>.</li>
<li id="_note-Cooper2006"><b><a href="#_ref-Cooper2006_0" title="">^</a></b> Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, et al. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;list_uids=16760444&amp;dopt=ExternalLink" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;list_uids=16760444&amp;dopt=ExternalLink" rel="nofollow">Major congenital malformations after first-trimester exposure to ACE inhibitors.</a> N Engl J Med 2006;354(23):2443-51. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16760444" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16760444">PMID 16760444</a></li>
<li id="_note-Luno2005"><b><a href="#_ref-Luno2005_0" title="">^</a></b> Luno J, Praga M, de Vinuesa SG. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Curr Pharm Des 2005;11(10):1291-300. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15853685" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15853685">PMID 15853685</a></li>
<li id="_note-vandeWal2005"><b><a href="#_ref-vandeWal2005_0" title="">^</a></b> van de Wal RM, van Veldhuisen DJ, van Gilst WH, Voors AA. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;list_uids=16105846&amp;dopt=ExternalLink" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;list_uids=16105846&amp;dopt=ExternalLink" rel="nofollow">Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?</a> Eur Heart J 2005;26(22):2361-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16105846" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16105846">PMID 16105846</a></li>
<li id="_note-Finnegan2003"><b><a href="#_ref-Finnegan2003_0" title="">^</a></b> Finnegan PM, Gleason BL. <a href="http://www.theannals.com/cgi/content/full/37/6/886" class="external text" title="http://www.theannals.com/cgi/content/full/37/6/886" rel="nofollow">Combination ACE inhibitors and angiotensin II receptor blockers for hypertension.</a> Ann Pharmacother 2003;37(6):886-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12773079" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12773079">PMID 12773079</a></li>
<li id="_note-Krum2004"><b><a href="#_ref-Krum2004_0" title="">^</a></b> Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6(7):937-45. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15556056" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15556056">PMID 15556056</a></li>
<li id="_note-Solomon2005"><b><a href="#_ref-Solomon2005_0" title="">^</a></b> Solomon SD, Skali H, Anavekar NS, et al. <a href="http://circ.ahajournals.org/cgi/content/full/111/25/3411" class="external text" title="http://circ.ahajournals.org/cgi/content/full/111/25/3411" rel="nofollow">Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.</a> Circulation 2005;111(25):3411-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15967846" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15967846">PMID 15967846</a></li>
<li id="_note-Yang2005"><b><a href="#_ref-Yang2005_0" title="">^</a></b> Yang Y, Ohta K, Shimizu M, et al. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 2005;64(1):35-40. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16047643" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16047643">PMID 16047643</a></li>
<li id="_note-Kevin"><b><a href="#_ref-Kevin_0" title="">^</a></b> K.K.F.Ng and J.R.Vane: Conversion of angiotensin I to angiotensin II. Nature 1967, 216, 762-766</li>
<li id="_note-Kevin2"><b><a href="#_ref-Kevin2_0" title="">^</a></b> K.K.F.Ng and J.R.Vane: Fate of angiotensin I in the circulation. Nature 1968, 218, 144-150.</li>
<li id="_note-Kevin3"><b><a href="#_ref-Kevin3_0" title="">^</a></b> K.K.F.Ng and J.R.Vane: Some properties of angiotensin converting enzyme in the lung in vivo. Nature 1970, 225, 1142-1144.</li>
</ol>
</div>
<div class="NavFrame" style="clear:both;">
<div class="NavHead" style="background:#ccccff;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap; position:absolute; width:auto; left:0.5em;"><a href="../../../a/c/e/Template%7EACE_inhibitors_5aaf.html" title="Template:ACE inhibitors"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../a/c/e/Template%7EACE_inhibitors_5aaf.html" class="external text" title="http://en.wikipedia.org../../../a/c/e/Template%7EACE_inhibitors_5aaf.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
<b><strong class="selflink">ACE inhibitors</strong> (<a href="../../../a/t/c/ATC_code_C09_6c4b.html#C09A_ACE_inhibitors.2C_plain" title="ATC code C09">C09A</a>)</b></div>
<div class="NavContent" style="margin:0.5em; font-size:0.9em;">
<p><a href="../../../b/e/n/Benazepril.html" title="Benazepril">Benazepril</a>, <a href="../../../c/a/p/Captopril.html" title="Captopril">Captopril</a>, <a href="../../../e/n/a/Enalapril.html" title="Enalapril">Enalapril</a>, <a href="../../../f/o/s/Fosinopril.html" title="Fosinopril">Fosinopril</a>, <a href="../../../l/i/s/Lisinopril.html" title="Lisinopril">Lisinopril</a>, <a href="../../../p/e/r/Perindopril.html" title="Perindopril">Perindopril</a>, <a href="../../../q/u/i/Quinapril.html" title="Quinapril">Quinapril</a>, <a href="../../../r/a/m/Ramipril.html" title="Ramipril">Ramipril</a>, <a href="../../../s/p/i/Spirapril.html" title="Spirapril">Spirapril</a>, <a href="../../../t/r/a/Trandolapril.html" title="Trandolapril">Trandolapril</a></p>
</div>
</div>
<table class="navbox collapsible autocollapse" style="margin: auto; text-align:left">
<tr>
<th colspan="2" style="text-align:center;">
<div style="float:left; text-align:left; width:6em;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap;"><a href="../../../m/a/j/Template%7EMajor_Drug_Groups_2544.html" title="Template:Major Drug Groups"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="../../../m/a/j/Template_talk%7EMajor_Drug_Groups_149b.html" title="Template talk:Major Drug Groups"><span title="Discussion about this template">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org../../../m/a/j/Template%7EMajor_Drug_Groups_2544.html" class="external text" title="http://en.wikipedia.org../../../m/a/j/Template%7EMajor_Drug_Groups_2544.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
</div>
Major Drug Groups</th>
</tr>
<tr>
<th style=""><a href="../../../b/r/a/Brain.html" title="Brain">Brain</a> and <a href="../../../n/e/r/Nervous_system.html" title="Nervous system">Nervous system</a></th>
<td style="" colspan="1"><a href="../../../a/n/a/Analgesic.html" title="Analgesic">Analgesics</a>, <a href="../../../a/n/e/Anesthesia.html" title="Anesthesia">Anesthetics</a>, <a href="../../../a/n/x/Anxiolytic.html" title="Anxiolytic">Anxiolytics</a>, <a href="../../../a/n/t/Antidepressant.html" title="Antidepressant">Antidepressants</a>, <a href="../../../a/n/t/Antipsychotic.html" title="Antipsychotic">Antipsychotics</a>, <a href="../../../a/n/t/Anticonvulsant.html" title="Anticonvulsant">Anticonvulsants</a>, <a href="../../../s/t/i/Stimulant.html" title="Stimulant">Nervous system stimulants</a>, <a href="../../../a/n/t/Antiemetic.html" title="Antiemetic">Antiemetics</a>, <a href="../../../p/s/y/Psychedelics%2C_dissociatives_and_deliriants.html" title="Psychedelics, dissociatives and deliriants">Hallucinogens</a>, <a href="../../../m/o/o/Mood_stabilizer.html" title="Mood stabilizer">Mood stabilizers</a></td>
</tr>
<tr>
<th style=""><a href="../../../r/e/s/Respiratory_system.html" title="Respiratory system">Respiratory system</a></th>
<td style="" colspan="1"><a href="../../../b/r/o/Bronchodilator.html" title="Bronchodilator">Bronchodilators</a>, <a href="../../../d/e/c/Decongestant.html" title="Decongestant">Decongestants</a></td>
</tr>
<tr>
<th style=""><a href="../../../h/e/a/Heart.html" title="Heart">Heart</a> and <a href="../../../c/i/r/Circulatory_system.html" title="Circulatory system">Circulation</a></th>
<td style="" colspan="1"><strong class="selflink">Angiotensin converting enzyme inhibitors</strong>, <a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Antiarrhythmic agent">Antiarrhythmics</a>, <a href="../../../a/n/t/Antianginal.html" title="Antianginal">Antianginals</a>, <a href="../../../a/n/t/Antihypertensive.html" title="Antihypertensive">Antihypertensives</a>, <a href="../../../h/y/p/Hypolipidemic_agent.html" title="Hypolipidemic agent">Antihyperlipidemics</a>, <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">Anticoagulants</a>, <a href="../../../a/n/t/Antiplatelet_drug.html" title="Antiplatelet drug">Antiplatelets</a>, <a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">Beta blockers</a>, <a href="../../../d/i/u/Diuretic.html" title="Diuretic">Diuretics</a>, <a href="../../../t/h/r/Thrombolytic_drug.html" title="Thrombolytic drug">Thrombolytics</a>, <a href="../../../v/a/s/Vasodilator.html" title="Vasodilator">Vasodilators</a></td>
</tr>
<tr>
<th style=""><a href="../../../g/a/s/Gastrointestinal_tract.html" title="Gastrointestinal tract">Gastrointestinal tract</a></th>
<td style="" colspan="1"><a href="../../../a/n/t/Antacid.html" title="Antacid">Antacids</a>, <a href="../../../a/n/t/Antidiarrhoeal.html" title="Antidiarrhoeal">Antidiarrhoeals</a>, <a href="../../../h/2/-/H2-receptor_antagonist.html" title="H2-receptor antagonist">H2-receptor antagonists</a>, <a href="../../../p/r/o/Proton_pump_inhibitor.html" title="Proton pump inhibitor">Proton pump inhibitors</a>, <a href="../../../l/a/x/Laxative.html" title="Laxative">Laxatives</a></td>
</tr>
<tr>
<th style=""><a href="../../../m/u/s/Muscle.html" title="Muscle">Muscles</a>, <a href="../../../b/o/n/Bone.html" title="Bone">Bones</a>, and <a href="../../../j/o/i/Joint.html" title="Joint">Joints</a></th>
<td style="" colspan="1"><a href="../../../a/n/t/Anti-inflammatory.html" title="Anti-inflammatory">Anti-inflammatories</a>, <a href="../../../d/i/s/Disease-modifying_antirheumatic_drug.html" title="Disease-modifying antirheumatic drug">Antirheumatics</a>, <a href="../../../c/o/r/Corticosteroid.html" title="Corticosteroid">Corticosteroids</a>, <a href="../../../m/u/s/Muscle_relaxant.html" title="Muscle relaxant">Muscle relaxants</a></td>
</tr>
<tr>
<th style=""><a href="../../../a/l/l/Allergy.html" title="Allergy">Allergy</a></th>
<td style="" colspan="1"><a href="../../../a/n/t/Antihistamine.html" title="Antihistamine">Antihistamines</a></td>
</tr>
<tr>
<th style=""><a href="../../../i/n/f/Infection.html" title="Infection">Infections</a> and <a href="../../../i/n/f/Infestation.html" title="Infestation">Infestations</a></th>
<td style="" colspan="1"><a href="../../../a/n/t/Antibiotic.html" title="Antibiotic">Antibiotics</a>, <a href="../../../a/n/t/Antiviral_drug.html" title="Antiviral drug">Antivirals</a>, <a href="../../../v/a/c/Vaccine.html" title="Vaccine">Vaccines</a>, <a href="../../../a/n/t/Antiprotozoal_agent.html" title="Antiprotozoal agent">Antiprotozoals</a>, <a href="../../../a/n/t/Antifungal_drug.html" title="Antifungal drug">Antifungals</a>, <a href="../../../a/n/t/Anthelmintic.html" title="Anthelmintic">Anthelmintics</a></td>
</tr>
<tr>
<th style=""><a href="../../../e/n/d/Endocrine_system.html" title="Endocrine system">Endocrine system</a></th>
<td style="" colspan="1"><a href="../../../c/o/r/Corticosteroid.html" title="Corticosteroid">Corticosteroids</a>, <a href="../../../a/n/t/Anti-diabetic_drug.html" title="Anti-diabetic drug">Anti-diabetics</a></td>
</tr>
<tr>
<th style=""><a href="../../../m/a/l/Malignant.html" title="Malignant">Malignant</a> and <a href="../../../i/m/m/Immune_system.html" title="Immune system">Immune</a> disease</th>
<td style="" colspan="1"><a href="../../../c/h/e/Chemotherapy.html" title="Chemotherapy">Anticancer agents</a>, <a href="../../../i/m/m/Immunosuppressive_drug.html" title="Immunosuppressive drug">Immunosuppressants</a></td>
</tr>
<tr>
<th style=""><a href="../../../r/e/p/Reproductive_system.html" title="Reproductive system">Reproductive system</a></th>
<td style="" colspan="1"><a href="../../../h/o/r/Hormonal_contraception.html" title="Hormonal contraception">Hormonal contraception</a>, <a href="../../../f/e/r/Fertility_medication.html" title="Fertility medication">Fertility agents</a>, <a href="../../../s/e/l/Selective_estrogen_receptor_modulator.html" title="Selective estrogen receptor modulator">Selective estrogen receptor modulators</a></td>
</tr>
<tr>
<th style=""><a href="../../../s/k/i/Skin.html" title="Skin">Skin</a></th>
<td style="" colspan="1"><a href="../../../a/n/t/Antipruritic.html" title="Antipruritic">Antipruritics</a></td>
</tr>
</table>
<p><span id="interwiki-de-fa"></span></p>

<!-- 
Pre-expand include size: 20397 bytes
Post-expand include size: 15649 bytes
Template argument size: 6429 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/c/e/ACE_inhibitor_fd43.html">http://en.wikipedia.org../../../a/c/e/ACE_inhibitor_fd43.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../a/c/e/Category%7EACE_inhibitors_360c.html" title="Category:ACE inhibitors">ACE inhibitors</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/c/e/ACE_inhibitor_fd43.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/c/e/Talk%7EACE_inhibitor_0134.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/ACE_inhibitor">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/a/c/e/ACE-Hemmer_db29.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../es/i/e/c/IECA_ec98.html">Español</a>
	      </li>
	      	      <li>
	      <a href="../../../../fr/i/n/h/Inhibiteur_de_l%27enzyme_de_conversion.html">Français</a>
	      </li>
	      	      <li>
	      <a href="../../../../it/a/c/e/ACE-inibitori_875c.html">Italiano</a>
	      </li>
	      	      <li>
	      <a href="../../../../nl/a/c/e/ACE-remmer_486f.html">Nederlands</a>
	      </li>
	      	      <li>
	      <a href="../../../../ja/a/c/e/ACE%E9%98%BB%E5%AE%B3%E8%96%AC_f83a.html">日本語</a>
	      </li>
	      	      <li>
	      <a href="../../../../nn/a/c/e/ACE-hemmar_defc.html">‪Norsk (nynorsk)‬</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/i/n/h/Inhibitory_konwertazy_angiotensyny.html">Polski</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/i/e/c/IECA_ec98.html">Português</a>
	      </li>
	      	      <li>
	      <a href="../../../../th/%E0%B9%80/%E0%B8%AD/%E0%B8%8B/%E0%B9%80%E0%B8%AD%E0%B8%8B%E0%B8%B5%E0%B8%AD%E0%B8%B5%E0%B8%AD%E0%B8%B4%E0%B8%99%E0%B8%AE%E0%B8%B4%E0%B8%9A%E0%B8%B4%E0%B9%80%E0%B8%95%E0%B8%AD%E0%B8%A3%E0%B9%8C.html">ไทย</a>
	      </li>
	      	      <li>
	      <a href="../../../../zh/%E8%A1%80/%E7%AE%A1/%E7%B4%A7/%E8%A1%80%E7%AE%A1%E7%B4%A7%E5%BC%A0%E7%B4%A0%E8%BD%AC%E5%8C%96%E9%85%B6%E6%8A%91%E5%88%B6%E5%89%82.html">中文</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 23:46, 20 March 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../c/h/o/User%7EChochopk_5bb4.html" title="User:Chochopk">Chochopk</a>, <a href="../../../b/e/n/User%7EBenjaminevans82_7c6f.html" title="User:Benjaminevans82">Benjaminevans82</a>, <a href="../../../f/r/e/User%7EFreplySpang_52d7.html" title="User:FreplySpang">FreplySpang</a>, <a href="../../../c/h/r/User%7EChristopher_Parham_7957.html" title="User:Christopher Parham">Christopher Parham</a>, <a href="../../../j/e/r/User%7EJerry_f493.html" title="User:Jerry">Jerry</a>, <a href="../../../k/a/z/User%7EKazubon_ffe0.html" title="User:Kazubon">Kazubon</a>, Toupster, <a href="../../../s/t/b/User%7ESTBotD_8c4f.html" title="User:STBotD">STBotD</a>, Wmk1605, <a href="../../../e/d/w/User%7EEdward_42f0.html" title="User:Edward">Edward</a>, <a href="../../../t/h/i/User%7EThijs%21bot_bdf4.html" title="User:Thijs!bot">Thijs!bot</a>, <a href="../../../g/e/n/User%7EGeneb1955_ac1e.html" title="User:Geneb1955">Geneb1955</a>, <a href="../../../n/m/g/User%7ENmg20_469b.html" title="User:Nmg20">Nmg20</a>, <a href="../../../r/m/k/User%7ERmky87_07f5.html" title="User:Rmky87">Rmky87</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../y/u/r/User%7EYurikBot_b393.html" title="User:YurikBot">YurikBot</a>, <a href="../../../e/p/o/User%7EEpolk_d8a6.html" title="User:Epolk">Epolk</a>, <a href="../../../t/e/c/User%7ETechelf_1565.html" title="User:Techelf">Techelf</a>, <a href="../../../e/s/k/User%7EEskimbot_5fb5.html" title="User:Eskimbot">Eskimbot</a>, Samarat, Sethnk, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, <a href="../../../n/u/n/User%7ENunh-huh_d05a.html" title="User:Nunh-huh">Nunh-huh</a>, <a href="../../../u/t/h/User%7EUthbrian_6843.html" title="User:Uthbrian">Uthbrian</a>, <a href="../../../r/o/b/User%7ERoboDick_615f.html" title="User:RoboDick">RoboDick</a>, <a href="../../../m/c/e/User%7EMceder_5657.html" title="User:Mceder">Mceder</a>, <a href="../../../c/a/c/User%7ECacycle_6f2f.html" title="User:Cacycle">Cacycle</a>, <a href="../../../p/i/x/User%7EPixeltoo_1608.html" title="User:Pixeltoo">Pixeltoo</a>, <a href="../../../j/a/x/User%7EJaxl_09f9.html" title="User:Jaxl">Jaxl</a>, <a href="../../../g/m/a/User%7EGmaxwell_5150.html" title="User:Gmaxwell">Gmaxwell</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../s/a/l/User%7ESalvadorjo_220f.html" title="User:Salvadorjo">Salvadorjo</a>, <a href="../../../v/u/o/User%7EVuo_9d94.html" title="User:Vuo">Vuo</a>, <a href="../../../b/j/a/User%7EBjarteSorensen_ac43.html" title="User:BjarteSorensen">BjarteSorensen</a>, <a href="../../../b/i/g/User%7EBignoter_5b59.html" title="User:Bignoter">Bignoter</a>, <a href="../../../p/e/t/User%7EPetersam_7af3.html" title="User:Petersam">Petersam</a>, <a href="../../../c/o/n/User%7EConti_fae9.html" title="User:Conti">Conti</a>, <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>, <a href="../../../j/u/m/User%7EJumbuck_a815.html" title="User:Jumbuck">Jumbuck</a>, <a href="../../../v/i/n/User%7EVina_6603.html" title="User:Vina">Vina</a>, <a href="../../../j/p/h/User%7EJph_7c89.html" title="User:Jph">Jph</a>, <a href="../../../g/u/a/User%7EGuanabot_b902.html" title="User:Guanabot">Guanabot</a>, <a href="../../../p/f/h/User%7EPFHLai_0319.html" title="User:PFHLai">PFHLai</a>, <a href="../../../k/p/j/User%7EKpjas_9cb5.html" title="User:Kpjas">Kpjas</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../e/e/q/User%7EEequor_b13d.html" title="User:Eequor">Eequor</a>, <a href="../../../t/o/p/User%7ETopbanana_c4c6.html" title="User:Topbanana">Topbanana</a>, <a href="../../../h/u/g/User%7EHugh2414_a633.html" title="User:Hugh2414">Hugh2414</a>, <a href="../../../1/6/8/User%7E168....html" title="User:168...">168...</a>, <a href="../../../m/a/r/User%7EMarj_Tiefert_437d.html" title="User:Marj Tiefert">Marj Tiefert</a>, <a href="../../../m/a/l/User%7EMalcolm_Farmer_a328.html" title="User:Malcolm Farmer">Malcolm Farmer</a> and <a href="../../../t/w/o/User%7ETwoOneTwo_b3fe.html" title="User:TwoOneTwo">TwoOneTwo</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
